Immunicum today announced that phase I/II data has been presented during a general poster session at the American Society of Clinical Oncology (ASCO) 2014 annual meeting on the Company’s clinical candidate, INTUVAX, in patients with metastasized renal cell carcinoma (mRCC).
In addition to demonstrating a favorable safety profile, INTUVAX, as a single agent, has shown clear signs of tumor specific immune activation and encouraging survival data for patients with poor prognosis. Furthermore, preliminary data indicate a synergistic effect between INTUVAX and subsequent treatment with tyrosine kinase inhibitors (TKIs).
Read the press release here: Press release 140602 – ASCO data released
Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4913